

**PATENT ASSIGNMENT**

Electronic Version v1.1  
 Stylesheet Version v1.1

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
CLF Medical Technology Acceleration Program, Inc.	04/13/2005
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	Albany Medical College
<b>Street Address:</b>	47 New Scotland Avenue
<b>City:</b>	Albany
<b>State/Country:</b>	NEW YORK
<b>Postal Code:</b>	12208
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	11789762
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)542-2241
<i>Correspondence will be sent via US Mail when the fax attempt is unsuccessful.</i>	
<b>Phone:</b>	617 542-6000
<b>Email:</b>	sjlavigne@mintz.com
<b>Correspondent Name:</b>	Erica Carlson
<b>Address Line 1:</b>	One Financial Center
<b>Address Line 4:</b>	Boston, MASSACHUSETTS 02111
<b>ATTORNEY DOCKET NUMBER:</b>	29708-501 CIP DIV
<b>NAME OF SUBMITTER:</b>	Erica R. Carlson
<b>Total Attachments: 4</b> source=29708501CIPDIV_Assignment2#page1.tif source=29708501CIPDIV_Assignment2#page2.tif source=29708501CIPDIV_Assignment2#page3.tif source=29708501CIPDIV_Assignment2#page4.tif	

OP \$40.00 11789762

Express Mail Label No.: EV473991259US  
Date of Deposit: April 22, 2005

Attorney Docket No.: 29708-501, DIV, CIP  
29708-502

## ASSIGNMENT

**CLF Medical Technology Acceleration Program, Inc.**, a non-profit corporation having principal offices at 747 Pierce Road, Clifton Park, NY 12065 ("ASSIGNOR"), the undersigned, for good and valuable consideration, the receipt of which is hereby acknowledged, hereby assigns, sells and transfers to **Albany Medical College**, a non-profit corporation having principal offices at 47 New Scotland Avenue, Albany, NY 12208, and its successors, assigns and legal representatives, all hereinafter referred to as the ASSIGNEE: (1) the entire right, title and interest for the United States and in all countries, in and to any and all inventions, discoveries and applications which are disclosed in the patents and applications for patents as listed in Schedule A, including any renewals, revivals, reissues, reexaminations, extensions, continuations and divisions thereof and any substitute applications therefor; (2) the full and complete right to file patent applications in the name of the ASSIGNEE, its designee, or in the name of CLF Medical Technology Acceleration Program, Inc. at the ASSIGNEE, or its designee's election, on the aforesaid inventions, discoveries and applications in all countries of the world; (3) the entire right, title and interest in and to any Letters Patents which may issue thereon in the United States or in any country, and any renewals, revivals, reissues, reexaminations and extensions thereof, and any patents of confirmation, registration and importation of the same; and (4) the entire right, title and interest in all Convention and Treaty Rights of all kinds thereon, including without limitation all rights of priority in any country of the world, in and to the above inventions, discoveries and applications.

CLF Medical Technology Acceleration Program, Inc. hereby authorizes and requests the competent authorities to grant and to issue any and all such Letters Patent in the United States and throughout the world to the ASSIGNEE of the entire right, title and interest therein, as fully and entirely as the same would have been held and enjoyed by CLF Medical Technology Acceleration Program, Inc. had this assignment, sale and transfer not been made.

CLF Medical Technology Acceleration Program, Inc. agrees, at any time, upon the request of the ASSIGNEE, to execute and to deliver to the ASSIGNEE any additional applications for patents for said inventions and discoveries, or any part or parts thereof, and any applications for patents of confirmation, registration and importation based on any Letters Patent issuing on said inventions, discoveries, or applications and divisions, continuations, renewals, revivals, reissues, reexaminations and extensions thereof.


CLF Medical Technology Acceleration Program, Inc. further agrees at any time to execute and to deliver upon request of the ASSIGNEE such additional documents, if any, as are necessary or desirable to secure patent protection on said inventions, discoveries and applications throughout all countries of the world, and otherwise to do that necessary to give full effect to and to perfect the rights of the ASSIGNEE under this Assignment, including the execution, delivery and procurement of any and all further documents evidencing this assignment, transfer and sale as may be necessary or desirable.

CLF Medical Technology Acceleration Program, Inc. hereby covenants that it has obtained full right to convey the entire interests listed in Schedule A by virtue of prior assignments, and that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this assignment.

CLF Medical Technology Acceleration Program, Inc. further covenants that ASSIGNEE will, upon its request, be provided promptly with all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible to ASSIGNOR and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to ASSIGNEE or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.


**For CLF Medical Technology Acceleration Program, Inc.:**

Date: 4/13/05

  
Signature of: **Richard C. Liebich**  
Title: **Chief Executive Officer**  
**CLF Medical Technology Acceleration Program, Inc.**

State of MA  
County of Suffolk

Subscribed and sworn to before me that he/she/they executed the instrument in his/her/their authorized capacity, and that in so doing, the entity upon behalf of which the person(s) acted, executed the instrument this 13<sup>th</sup> day of April, 2005

  
Notary Public

My commission expires 1-20-06

**SCHEDULE A**

Country	Title	Application No.	Parent No.	Assignment Reel and Frame Nos.	Mini Docket No.
US	Leptin-Related Peptides	09/377,081	6,777,388	1) R#013744, F# 0724; 2) R#013744, F#0706; 3) R#013744, F#0711	29708-501
US	Leptin-Related Peptides	10/458,334; DIV of 09/377,081	Pending	same as above	29708-501 DIV
US	Leptin-Related Peptides	10/698,510; CIP of 09/377,081	Pending	1) R# 015771, F#0809	29708-501 CIP
AU	Leptin-Related Peptides	199955759	772278	N/A	29708-501-004
CA	Leptin-Related Peptides	2340470	Pending	N/A	29708-501-008
EP	Leptin-Related Peptides	99942363.5	Abandoned	N/A	29708-501-019
PCT	Leptin-Related Peptides	PCT/US03/03482 0	Pending	N/A	29708-501-061 CIP

US	Calcineurin Modulators	10/194,155	Pending	1) R# 013703, F# 0758 2) R# 013703, F# 0764 3) R# 013703, F# 0777	29708-502
----	------------------------	------------	---------	---	-----------

TRA 2025330v1